ClinicalTrials.gov
Cure8 trial brief
E-nose in Evaluating Colitis Activity
Tests and monitoring
Fecal calprotectin
Intestinal ultrasound
Clinical Trial Phase 1
Inflammatory bowel disease
Crohn's disease
Why This Matters
A rapid stool molecular test could offer a noninvasive way to measure inflammation, predict relapse, and monitor treatment response in children with IBD—areas where current tests have limitations.
Who Should Pay Attention
Pediatric patients with IBD, parents/caregivers, pediatric gastroenterologists, and researchers working on noninvasive biomarkers or stool diagnostics.
Study Snapshot
Story typeClinical Reference
Evidence typeClinical trial
Enrollment120 participants
Study statusNot_yet_recruiting
Source depthTrial registry record
What To Know
This is a not-yet-recruiting observational study at Tampere University Hospital enrolling children scheduled for colonoscopy. Stool samples collected for routine fecal calprotectin testing will also be analyzed by DMS to generate a ‘‘fecal molecular profile’’ (FMP).
Researchers will compare FMPs between children with and without IBD, between active disease and remission, and over time during up to 5 years of follow-up to see if profiles predict relapse or treatment escalation.
The study focuses on collecting stool and routine clinical data (symptom scores, blood tests, intestinal ultrasound, elastography, and clinically indicated biopsies) rather than adding invasive procedures. If successful, the approach could become a rapid, noninvasive adjunct to existing monitoring tools.
Keep In Mind
This is an observational trial protocol (not yet recruiting) testing a technology (DMS) for fecal molecular profiling alongside routine tests; findings would need further validation before clinical use.
Source Details
Review the original publication for the complete reporting, methods, and context.
Clinical trial
Evidence type derived from source or registry metadata.
PublicationClinicalTrials.gov
SponsorTampere University Hospital
Trial IDNCT07781215
Study typeObservational
Enrollment120 participants
Indexed viaClinicalTrials.gov
Source typeTrial registry record
PublishedAug 24, 2026, 12:00 AM
Content availableTrial registry record
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Emerging role of intestinal ultrasound in detecting postoperative recurrence in Crohn's disease.
Noninvasive tools that reliably detect postoperative recurrence could reduce the need for frequent invasive endoscopy and help target earlier intervention for people with Crohn's disease after surgery.
Intestinal Ultrasound Plus Fecal Calprotectin Predicts Crohn's Recurrence | Docwire News
Noninvasive tests at 3 months after ileocecal resection (ultrasound + fecal calprotectin) may identify patients at high risk of endoscopic recurrence by 6 months. That could help avoid or target postoperative endoscopy...
Dual Testing Strategy Linked to Long-Term Benefits in Crohn's Disease - Medscape
This study suggests using both faecal calprotectin and intestinal ultrasound together can better identify patients who reach deeper, transmural healing — and those patients had lower risk of bowel-damage progression....